FDA Expands Use of Dapagliflozin to Broader Range of HF

The SGLT2 inhibitor is now indicated for treatment of heart failure across the full spectrum of left-ventricular ejection fraction ― including HF with mildly reduced and preserved ejection fraction.
Medscape Medical News

source https://www.medscape.com/viewarticle/991736?src=rss

Comments

Popular posts from this blog

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?